Nahajate se tukaj
Novice
29. 6. 2017
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
27. 6. 2017
Servier is the first French pharmaceutical company to partner with Plug and Play Health & Wellness
31. 5. 2017
Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose interleukin-2 for the treatment of autoimmune diseases
3. 5. 2017
Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
26. 4. 2017
Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
25. 4. 2017
Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
28. 3. 2017
Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market
27. 3. 2017
Dr Claude Bertrand, General Director of Research and Development at Servier
16. 3. 2017
Servier Research Fellowship awarded by the International Union of Phlebology - Union Internationale de Phlébologie / 2017-2019 submission
14. 3. 2017
Servier and Neurochlore join forces to treat autism in children
14. 3. 2017
Cessation of marketing of Protelos/Osseor: Extract of the letter sent to European Medicine Agency (EMA) and national European Agencies on 10 February 2017
9. 3. 2017
Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
6. 3. 2017
Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.
3. 3. 2017
Servier successfully issues euro private placement
1. 3. 2017
Bolniki z napredovanim metastatskim kolorektalnim rakom (mKRR) imajo v Sloveniji na voljo novo zdravilo
14. 2. 2017
Servier and GAIA extend their partnership to provide patients around the world with deprexis®, an internet-based cognitive behavioral therapy for depression
7. 2. 2017
Servier announces an increase in turnover for 2015-2016
18. 1. 2017
Servier appoints MaSTherCell for the development of its CAR-T cell therapy manufacturing platform
5. 1. 2017
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
28. 12. 2016
OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
7. 12. 2016
GeNeuro and Servier announce ANGEL-MS extension clinical study in multiple sclerosis
8. 11. 2016
Servier signs agreement with non-profit association La Chaîne de l'Espoir and announces creation of the Mécénat Servier endowment fund
20. 10. 2016
New compound shows promise in treating multiple human cancers
1. 9. 2016
Amgen and Servier extend Omecamtiv Mecarbil collaboration in Chronic Heart Failure
27. 7. 2016
Servier invests in bioproduction in France
11. 7. 2016
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
27. 4. 2016
Evropskim bolnikom z napredovalim metastatskim kolorektalnim rakom je zdaj na voljo novo zdravilo LONSURF® (trifluridin/tipiracil), ki je pridobilo dovoljenje za promet v Evropi
22. 4. 2016
ISHR-ES – Servier Research Fellowship 2016 awarded to Dr Hector Cabrera-Fuentes
6. 4. 2016
40th year of operations in Brazil
1. 4. 2016
Withdrawal of fusafungine-containing medicines from the market
26. 2. 2016
Servier je pridobil pozitivno mnenje odbora CHMP za zdravilo Lonsurf® (trifluridin/tipiracil) za zdravljenje neodzivnega metastatskega kolorektalnega raka
12. 2. 2016
EMA Benefit/Risk Revision of Fusafungine-Containing Medicines
11.1.2016
Spectrum Pharmaceuticals Signs a Strategic Partnership with Servier Canada
18. 12. 2015
GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment
7. 12. 2015
Servier announces expansion of collaboration for the development and commercialization of anticancer drug candidates targeting apoptosis
20. 11. 2015
Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier
19. 11. 2015
Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies
14. 10. 2015
Professor Félix Rey, winner of the 2015 Pasteur-Weizmann / Servier Award, for his work in the field of emerging pathogenic viruses
7. 10. 2015
ISHR-ES – Servier Research Fellowship 2016 / Deadline for applications: December 15, 2015
7. 10. 2015
Horizon Discovery Group plc In-licenses Oncology Programme from Servier and Enters Option Agreement
5. 10. 2015
Crossbeta and Servier announce strategic oligomer-based research collaboration in neurological diseases involving misfolded proteins
5. 10. 2015
Servier offers its expertise in industrial R&D, chemical synthesis and pharmaceutical manufacturing to partners.
24. 09. 2015
Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial
01. 04. 2015
An ESCEO-IOF/Servier Achievement Award: the 2015 Pierre Delmas Prize winner is Professor Jean-Yves Reginster
02. 11. 2014
G. B. Morgagni Prizes 2014 Winners
06. 08. 2015
ISHR-ES – Servier Research Fellowship 2015 awarded to Dr Pietro Ameri
06. 08. 2015
SERVIER Award in Microcirculation: the winners are Claudia Nussbaum and Sarah Bannenberg
06. 08. 2015
SERVIER Research Grant in Hypertension: the winner is Dr Sébastien Foulquier
09. 07. 2014
Cellectis Reaches Milestone in Servier Collaboration
17. 06. 2015
VECT-HORUS announces the signing of a scientific collaboration agreement with SERVIER
15. 06. 2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
04. 06. 2015
2015-2017 Winner of the UIP/Servier Fellowship
16. 04. 2015
FDA approves ivabradine for patients with chronic heart failure
01. 04. 2015
Servier Initiates Phase 2 Study of Gevokizumab in Patients with Diabetic Nephropathy
26. 01. 2015
Hybrigenics extends its partnership with Servier in the field of Ubiquitin-Specific Proteases inhibitors
26. 01. 2015
FDA approval of antihypertensive Prestalia® A codevelopment by Symplmed and Servier
Več informacij: www.servier.com
Servier Communication Department
Tel: +33 1 5572 6037
Email: presse@servier.fr